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Key Points
Using a systematic approach, we identified 23 prognostic factors for venous thromboembolism and
15 for bleeding.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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We identified several prognostic factors for VTE and bleeding that are not considered in most of the
widely used risk assessment models.

Abstract
There may be many predictors of venous thromboembolism (VTE) and bleeding in hospitalized medical
patients, but until now, systematic reviews and assessments of the certainty of the evidence have not been
published. We conducted a systematic review to identify prognostic factors for VTE and bleeding in
hospitalized medical patients and searched Medline and EMBASE from inception through May 2018. We
considered studies that identified potential prognostic factors for VTE and bleeding in hospitalized adult
medical patients. Reviewers extracted data in duplicate and independently and assessed the certainty of the
evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Of
69 410 citations, we included 17 studies in our analysis: 14 that reported on VTE, and 3 that reported on
bleeding. For VTE, moderate-certainty evidence showed a probable association with older age; elevated Creactive protein (CRP), D-dimer, and fibrinogen levels; tachycardia; thrombocytosis; leukocytosis; fever;
leg edema; lower Barthel Index (BI) score; immobility; paresis; previous history of VTE; thrombophilia;
malignancy; critical illness; and infections. For bleeding, moderate-certainty evidence showed a probable
association with older age, sex, anemia, obesity, low hemoglobin, gastroduodenal ulcers, rehospitalization,
critical illness, thrombocytopenia, blood dyscrasias, hepatic disease, renal failure, antithrombotic
medication, and presence of a central venous catheter. Elevated CRP, a lower BI, a history of malignancy,
and elevated heart rate are not included in most VTE risk assessment models. This study informs risk
prediction in the management of hospitalized medical patients for VTE and bleeding; it also informs
guidelines for VTE prevention and future research.

Visual Abstract
Introduction
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism
(PE), has an annual incidence of ∼1 per 1000 in adult populations.1,2 VTE is a major burden in
hospitalized medical patients. Medical patients can be classified as having acute, critical, or chronic
medical illness, and their risk for both VTE and bleeding may depend on the severity of their medical
illness. The incidence of VTE in hospitalized acutely ill medical patients detected by screening is up to
14.9%.3 From 50% to 70% of symptomatic VTEs and 70% to 80% of fatal PEs occur in acute medically ill
patients.4-7
The risk of hospital-acquired VTE is reduced by using pharmacological and nonpharmacological
interventions, but these interventions are not without potential patient harms. Risk assessment models
(RAMs) have been used in hospitalized medically ill patients to stratify the different subsets of patients by
their risk of having a VTE or clinically significant bleeding event.8 This stratification may then support
optimized management for the prevention of either outcome.9 A RAM is a formal combination of multiple
predictors from which risks of a specific end point can be calculated for individuals. The value of using
RAMs include generation of specific baseline risks to inform recommendations for a strata of patients and
calculation of a predicted risk of an outcome for an individual patient (eg, VTE or bleeding) based on the
patient’s characteristics (ie, the prognostic factors). Implementation of RAMs in the field of VTE
prevention can be accomplished by embedding them in clinical encounters or decision aids to individualize
the use of guideline recommendations. However, the application of RAMs is variable in current practice.3
Most RAMs are developed using data registries that are not based on a systematic review of all potential
prognostic factors.10 However, guiding principles for developing RAMs describe the importance of
identifying prognostic factors through systematic reviews.10 We identified only one systematic review,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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conducted 11 years ago, that evaluated VTE as an outcome in medical patients, but the effect sizes of the
prognostic factors were not subjected to meta-analysis, and bleeding risk, critical for balancing benefits
and harms in these patients, was not included as an outcome.11
Therefore, our aim was to conduct a systematic review of prognostic factors for VTE and bleeding in
hospitalized medical patients that may inform management, future guideline recommendations, and the
development of RAMs in hospitalized medical patients.

Methods
We conducted a systematic review using Cochrane methodology to identify studies that reported on
prognostic factors for VTE and bleeding in hospitalized medical patients.12 We developed a protocol that
was reviewed and revised by the coauthors, but we did not register it because of confidentiality clauses in
the research contract.
Data sources and searches
We searched Medline and EMBASE from inception through May 2018 with the assistance of an
information scientist. Supplemental Table 1 (available on the Blood Web site) provides detailed
descriptions of the search strategy. The search included both medical subject heading (MesH) terms and
text-word terms. It combined VTE-related terms with primary prevention terms and 2 search blocks
defining prognosis and prediction guide filters. We used no language restrictions or time limits.
Study selection
Four teams of 2 reviewers participated in training and calibration exercises before starting the screening
processes. The teams screened independently and in duplicate the titles and abstracts of all the retrieved
citations. They then retrieved the full texts of all citations judged as potentially eligible by at least 1 of the
reviewers on each team. The reviewers screened the full texts independently and in duplicate and
compared their results. A third senior reviewer resolved disagreements when necessary. Reviewers used a
standardized screening form and conducted calibration exercises before the screening process. The
eligibility criteria for study selection comprised the following characteristics.
Population We included studies that evaluated adult medical patients who were acutely, critically, or

chronically ill. We also included studies in which the population included nonmedical patients or medical
patients with a recent history of surgery or trauma if the final regression model adjusted for these factors.
We included studies if less than 10% of the population was receiving thromboprophylaxis or if the
statistical analysis adjusted for the use of thromboprophylaxis. Thromboprophylaxis included the use of
anticoagulation therapy (ie, warfarin, low-molecular-weight heparin, and unfractionated heparin),
antiplatelet therapy (ie, aspirin), or mechanical prophylaxis (ie, elastic stockings or intermittent pneumatic
compression).
We excluded studies if the population did not reflect the general population of interest, such as studies of
only selected types of cancer patients.13,14 We defined acutely ill medical patients as those hospitalized for
a medical illness including heart failure, respiratory insufficiency, stroke, and infectious or inflammatory
diseases requiring urgent care.2 Critically ill patients were those who had an immediately life-threatening
condition and were admitted to an intensive or critical care unit.2 Chronically ill medical patients included
those with acute exacerbations of chronic medical conditions who required hospitalization.2
Exposure We investigated all prognostic factors reported in individual studies.
Comparisons We investigated the absence or different levels of the prognostic factor.
Outcomes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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Studies had to report on the outcomes VTE or bleeding. VTE was defined as any symptomatic or
asymptomatic DVT or PE within 90 days after discharge. Bleeding included major or nonmajor but
clinically significant bleeding within 90 days after discharge.8
Setting Studies that included patients who were admitted to a nonsurgical inpatient ward.
Type of study We included prognostic factor and RAM studies that are based on typologies of prognosis

proposed by Iorio and colleagues,15 founded on the PROGnosis RESearch Strategy (PROGRESS) Group
framework.16
Data extraction
Two reviewers abstracted data independently and in duplicate from all eligible studies using standardized
forms. Reviewers compared and discussed results and consulted a third reviewer in case of any
disagreement. We conducted calibration exercises and piloting of all forms before the start of the data
abstraction process. All eligible studies were published in English.
For all identified studies, RAMs, and prognostic factor studies, the reviewers abstracted data on the
following characteristics:
Study context (eg, country and year of publication)
Type of prediction model study (development, validation, and impact)
Study design (eg, cohort or case-control; duration of follow-up)
Population and their demographics (eg, sample size, age, number of centers, and administration of
prophylaxis and what type)
Outcomes (VTE and bleeding)
Prognostic factors, definitions, and measurement methods (including thresholds used for continuous
predictors)
Measures of association (eg, odds ratio [OR], risk ratio, and hazard ratio)

Quality assessment
Risk-of-bias assessment
We assessed the risk of bias in the included studies by using the Prediction Study Risk of Bias Assessment
Tool (PROBAST) for RAM studies17 and the Quality in Prognosis Studies tool (QUIPS) for prognostic
factor studies.18-20
Synthesis of findings and certainty of evidence assessment
We presented the results of the studies, including the individual prognostic factors, in both tabular and
narrative formats. We also described the identified prognostic factor studies and the measure of association
with the outcomes of interest. We performed an assessment of the certainty of evidence for each of the
prognostic factors per outcome, based on the GRADE approach.15 The approach considers the following
domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. We developed
evidence profiles and rated the overall certainty of evidence as high, moderate, and low or very low,
depending on the grading of the individual domains.15 We narratively described the strength of the
association using the terms “there is,” “there probably is,” or “there may be,” depending on whether the
quality of the evidence was “high,” “moderate,” or “low/very low,” respectively.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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Data synthesis and analysis
We standardized the units of measurement for each prognostic factor, unifying the direction of the
predictors, adjusting the weights of the studies, and calculating crude-effect estimates when not
provided.21 When possible, we performed meta-analysis of all prognostic factors associated with the
outcomes VTE and bleeding that were reported by more than 1 study. We then presented the effect
estimate as OR and the corresponding 95% confidence interval (CI). In studies that reported the measure
of association as an hazard ratio or risk ratio, we converted them to ORs using the baseline risk (incidence
of those not on prophylaxis having VTE or bleeding out of the total sample) reported in the studies.22,23
We conducted a meta-analysis of associations using the generic inverse variance-based method to produce
an overall measure of association. We used the crude effect estimates when the adjusted estimates were not
provided. We explored consistency of the associations between the results of our meta-analysis and studies
reporting the same predictors that could not be pooled. All analyses used random-effect models applying
the prognosis module in Review Manager, version 5.3.24

Results
Figure 1 is a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart. Our search
identified 69 410 citations, of which we included 807 studies for full text assessment. Seventeen studies
fulfilled the inclusion criteria for evaluating VTE or bleeding outcomes or both.7,8,25-39
Description of included studies
Table 1 describes the characteristics of the included studies reporting on the outcomes VTE and/or
bleeding. Eight studies were prognostic factor studies: 4 were prognostic model development studies, and
5 were external validation studies. Five studies were retrospective case-control studies,25-29 2 of which
were multicenter25,26; 5 were retrospective cohorts,30-34 3 of which were multicenter.31,32,34 Seven
studies were prospective cohorts,7,8,35-39 4 of which were multicenter.7,8,36,39 The included studies were
conducted in the United States (n = 9), China (n = 3), Canada (n = 2), United Kingdom (n = 1), Poland (n
= 1), and Japan (n = 1). Of the 14 included studies for VTE (defined as proximal DVT or PE), 9 reported
on symptomatic VTE only.7,25-31,34 The other 5 studies reported on both symptomatic and asymptomatic
VTE.35-39 The follow-up time was up to 3 months in 12 of 14 studies reporting on VTE. The other 2
studies, Zhou et al29 and Yi et al,39 had a follow-up time of 6 months and 1 year, respectively, but also
reported the occurrence of VTE during hospitalization. In accordance with our protocol, we used the
incidence of VTE during hospitalization from those studies. The 3 studies that reported on bleeding (major
or clinically relevant) had a follow-up time up to 1 month.8,32,33 Of the 14 studies reporting on VTE, 12
studies included patients who received thromboprophylaxis in 0.4% to 67% of the patients. Of those, 2
studies35,36 included less than 10% of patients on thromboprophylaxis, and 10 studies adjusted for
prophylaxis in the statistical analysis.7,26-31,34,38,39 As for bleeding, all 3 studies reported prophylaxis use
in 9% to 70%, which was accounted for in their analysis.8,32,33
Risk-of-bias assessment
Risk of bias was serious across all identified studies, each presenting risk of bias in at least 1 domain or
item (Tables 2 and 3). Among the 17 included studies, 10 were retrospective, which may have introduced
classification bias.25-34 Seven of the 8 prognostic factor studies included only the variables significant in
bivariable analysis in their final regression model and did not present any data for nonsignificant predictors
in their adjusted analysis.30,32,33,36-39 Two of the 8 prognostic factor studies32,33 and 4 of the 9 prognostic
model development or validation studies did not have a clear description of appropriate outcome

26 29
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26-29

measurement.
We detected no evidence of publication bias through visual assessment of asymmetry
of the funnel plot for each pooled predictor in those that included at least 10 studies (Tables 2 and 3).
Supplemental Table 2 provides the detailed judgements for each of the risk-of-bias domain criteria.
Prognostic factors for VTE in hospitalized medical patients
Investigated were 29 candidate prognostic factors for VTE from 14 studies including 15 1 714 patients.
Table 2 provides the evidence profile for VTE-related prognostic factors. Supplemental Figure 1 provides
the forest plots of the meta-analysis of each of the prognostic factors.
Demographic factors We found moderate-certainty evidence that there is probably an association

between risk of any VTE and age ≥60 y (OR, 1.34; 95% CI, 1.17-1.55),7,25-27,29,31,34-37,39 and that there
is probably little to no association between risk of any VTE and sex (males vs females: OR, 1.03; 95% CI,
0.80-1.33).27,34-37
Functional factors There was moderate-certainty evidence for a probable association between risk of any

VTE and lower Barthel Index scores (BI ≤ 9; OR, 8.30; 95% CI, 2.70-25.52)37; immobility, defined as
confinement to bed for >72 hours or >7 days or bedridden or nonambulatory (OR, 3.17; 95% CI, 2.184.62)7,25,26,28,29,31,37,39; and paresis (OR, 2.97; 95% CI, 1.20-7.36).7,25,26,37

Medical illness and patient history factors We identified moderate-certainty evidence for an association

between risk of any VTE and history of VTE (OR, 6.08; 95% CI, 3.71-9.97)7,25-27,29-31,36; thrombophilia,
defined as familial or acquired disorder of the hemostatic system (OR, 5.88; 95% CI, 2.8012.35)7,25,26,29,34; history of malignancy (OR, 3.20; 95% CI, 2.14-4.79)27; active malignancy defined as
the presence of cancer on admission or within the past year (OR, 2.65; 95% CI, 1.793.91)7,25,27,28,30,31,34,36,37; critical illness, defined as intensive care unit (ICU) or coronary care unit
(CCU) stay or need for resuscitation (OR, 1.65; 95% CI, 1.39-1.95)7,25-27,29,34,36; and infections
including cellulitis, pneumonia, and sepsis (OR, 1.48; 95% CI, 1.16-1.89).27-29,31,36
We found low-certainty evidence that there may be an association between risk of any VTE and history of
heart failure (OR, of 2.68; 95% CI, 1.11-6.44)27,29,35; autoimmune diseases, including rheumatological
diseases and inflammatory diseases (OR, 2.33; 95% CI, 1.13-4.83)31,34,36,39; central venous catheter
(CVC) use (OR, 2.05; 95% CI, 0.74-5.65)31,34; and severe stroke, defined as acute ischemic stroke (OR,
1.79; 95% CI, 0.77-4.18).29,31,32,35,36 The findings for severe stroke when assessed using a diagnostic
tool, the National Institutes of Health Stroke Scale (NIHSS), were consistent with our results (Table 2).35
We also identified low-certainty evidence that there may be an association between risk of any VTE and
current tobacco use (OR, 1.59; 95% CI, 0.28-9.03); however, there may be little to no association between
risk of any VTE and previous tobacco use (OR, 0.97; 95% CI, 0.24-3.92).
Furthermore, we identified low-certainty evidence that there may be little to no association between the
risk of any VTE and respiratory failure (OR, 1.04; 95% CI, 0.69-1.58), coronary artery disease (CAD; OR,
1.01; 95% CI, 0.33-3.09), acute heart failure (OR, 0.82; 95% CI, 0.42-1.60),31,36 and hormone use (OR,
0.8; 95% CI, 0.36-1.78).29,31,36,37
We found very-low-certainty evidence that there may be little to no association between risk of any VTE
and chronic renal failure (OR, 0.76; 95% CI, 0.18-3.18).36
Laboratory and physical examination factors There is moderate-certainty evidence of an association

between risk of any VTE and C-reactive protein (CRP) >10 mg/L (OR, 10.10; 95% CI, 1.93-52.85)35 and
D-dimer >500 ng/mL at baseline (OR, 2.46; 95% CI, 1.19-5.10).36 The findings for D-dimer
concentration, when assessed as a continuous variable, were consistent with our results (Table 2).39 Also,
there is probably an association between risk of any VTE and elevated heart rate (>100 beats per minute;
2
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OR, 2.48; 95% CI, 1.66-3.71),27 thrombocytosis (platelet count, >350 × 109/L; OR, 2.16; 95% CI, 1.403.35),27,28 leukocytosis (white blood cell count, ≥11 × 109/L; OR, 1.91; 95% CI: 1.24-2.94),27 fever (body
temperature >38°C-38.5°C; OR, 1.88; 95% CI, 1.10-3.21),27,28 leg edema (OR, 1.88; 95% CI, 1.232.90),28,31 and elevated fibrinogen level (>400 mg/dL; OR, 0.18; 95% CI, 0.04-0.81).35
We identified low-certainty evidence that there may be an association between risk of any VTE and
varicose veins (OR, 1.53; 95% CI, 0.85-2.76)29,31 and obesity (BMI >30 kg/m2; OR, 1.34; 95% CI, 0.941.91).27,29,31,34,36
Additional analyses
We performed a sensitivity analysis, including studies that reported on immobility, to compare the
association between immobility >72 hours and >7 days with risk of VTE. We found similar effect
estimates for both categories with a slightly stronger association between immobility, defined as bed rest
for >7 days, and risk of VTE (OR, 3.67; 95% CI, 0.85-15.93) compared with immobility, defined as bed
rest for >72 hours, and risk of VTE (OR, 3.18; 95% CI, 1.10-9.16).
We also conducted a sensitivity analysis, including studies that reported on symptomatic VTE only, to
evaluate the influence of the studies that reported on both symptomatic and asymptomatic VTE. The
results of the sensitivity analysis showed similar effect estimates across prognostic factors except for CAD.
The association between CAD and risk of symptomatic VTE was somewhat stronger in the sensitivity
analysis of the 9 studies (OR, 2.02; 95% CI, 0.32-12.64), compared with little to no association with risk
of VTE in the primary analysis (OR, 1.01; 95% CI, 0.33-3.09; supplemental Table 4).
Prognostic factors for bleeding in medical hospitalized patients
Three studies including 160 142 patients investigated 17 candidate prognostic factors for bleeding. Table 3
provides the evidence profile for bleeding-related prognostic factors. Supplemental Figure 2 provides the
forest plots of the meta-analyses of each of the prognostic factors.
Demographic factors We found moderate-certainty evidence that there is probably an association

between risk of bleeding and age ≥65 (OR, 1.95; 95% CI, 1.59-2.38)8,32 and sex (males vs females; OR,
1.27; 95% CI, 1.09-1.47).8,32
Medical illness and patient history factors There was moderate-certainty evidence of a probable

association between risk of bleeding and gastroduodenal ulcers (OR, 2.74; 95% CI, 1.42-5.26),8,32
rehospitalization (OR, 2.39; 95% CI, 2.25- 2.54),32 critical illness including ICU or CCU stay (OR, 2.10;
95% CI, 1.42-3.11),8 and thrombocytopenia (OR, 1.79; 95% CI 0.97-3.29).8,32,33 When cutoffs for
thrombocytopenia were assessed separately, results showed that there probably is a greater magnitude of
association between risk of bleeding and platelet count <50 × 109/L compared with a platelet count ≥50 ×
109/L (OR, 3.37; 95% CI, 1.84-6.18),26 whereas a smaller magnitude of association between risk of
bleeding and platelet count <150 × 109/L compared with platelet count ≥150 × 109/L (OR, 1.30; 95% CI,
0.92-1.82).30,32 We also found moderate-certainty evidence that there is probably an association between
risk of bleeding and blood dyscrasia, defined as the presence of any bleeding disorder on admission (OR,
1.70; 95% CI, 1.60-1.81),32 hepatic disease (OR, 1.53; 95% CI, 1.09-2.15),8,32 and renal failure (OR,
1.43; 95% CI, 1.06-1.93).8,32 One study assessed renal failure by severity and the results showed that there
probably is a greater magnitude of association between risk of bleeding and severe renal failure
(glomerular filtration rate [GFR] <30 mL/min/m2) vs no severe renal failure (OR, 2.14; 95% CI, 1.223.75)8 and a smaller magnitude of association between risk of bleeding and moderate renal failure (GFR,
30-59 mL/min/m2) compared with no moderate renal failure (OR, 1.37; 95% CI, 0.84-2.23).8 We also
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identified moderate-certainty evidence that there is probably an association between risk of bleeding and
CVC use (OR, 1.37; 95% CI, 0.83-2.26)8,32 and antithrombotic medication use (OR, 1.28; 95% CI, 1.011.64).8,32
We found moderate-certainty evidence that there is probably little to no association between risk of
bleeding and hormone use, defined as estrogen intake (OR, 0.95; 95% CI, 0.82-1.10).32
Low-quality evidence showed that there may be an association between risk of bleeding and autoimmune
disease (OR, 1.30; 95% CI, 0.77-2.19).8,32 However, we identified low-certainty evidence that there may
be little to no association between risk of bleeding and malignancy (OR, 1.08; 95% CI, 0.42-2.77).8,32
Laboratory and physical examination factors There is moderate-certainty evidence of a probable

association between risk of bleeding and anemia as the reason for admission (OR, 5.15; 95% CI, 2.4510.81),8,33 morbid obesity (BMI ≥40 kg/m2; OR, 3.08; 95% CI, 1.35-7.02),33 and low hemoglobin (<13
g/dL in men and <11.5 g/dL in women; OR, 2.33; 95% CI, 1.04-5.22).33

Discussion
Summary of findings
We evaluated prognostic factors for VTE and bleeding in hospitalized medical patients. We identified 23
prognostic factors for VTE and 15 for bleeding, some supported by moderate certainty of the evidence.
Age, critical illness, CVC use, and autoimmune disease were prognostic of both outcomes. Obesity (BMI
>30 kg/m2) and morbid obesity (BMI >40 kg/m2) were associated with VTE and bleeding, respectively.
However, only age, critical illness, and autoimmune disease had the same quality of evidence for the 2
outcomes. This study is unique in many aspects including its comprehensiveness, the novelty of its
findings, and its transparent approach.
Strengths
Methodologically, our study benefits from the rigorous methods, the breadth of our search, our duplicate
and independent screening, the data abstraction process used, and our assessment of the certainty of
evidence on the basis of a structured framework. Also, we conducted sensitivity analyses to compare
different duration cutoffs for immobility and to address differences in type of outcome. Other strengths
include the involvement of a number of content and methodological experts.
Limitations and challenges
A potential limitation in terms of the search strategy was the focus on prevention, which we applied to
restrict the rather large number of citations that we identified in our searches and because we believed that
we would not miss relevant studies. To confirm this, we checked a large random sample (n = 3000) of
citations obtained from a search not including a restriction to the topic of prevention. We did not identify
any study that would have fulfilled the inclusion criteria and, therefore, our original search was unlikely to
have missed eligible studies. Also, time bias may be a potential limitation, as we identified some of the
prognostic factors from older studies. This may overestimate VTE events when considering overall trends
in the reduction of VTE events in hospitalized medical patients over time.
Potential limitations of the included studies relate to the inconsistency and variability across eligibility
criteria in the original studies and variability in study design, study type, sample size, and definitions of the
prognostic factors. Other challenges include inconsistency in methods of measurement used across studies
and contamination of the population with nonmedical hospitalized patients.
Implications for practice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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Our study identified candidate prognostic factors for VTE and bleeding that have been considered in the
analysis of some developed and widely used RAMs in daily practice, such as the Caprini, IMPROVE
(International Medical Prevention Registry on Venous Thromboembolism) VTE, IMPROVE bleed, and
Padua models.7,40-42 However, some factors that we identified as having a probable association with VTE,
based on our meta-analysis results, were not included or considered in the development of most of the
RAMs, such as elevated CRP >10 mg/L (OR, 10.10), lower BI scores (BI ≤ 9; OR, 8.30), history of
malignancy (OR, 3.20), and elevated heart rate (>100 beats/min; OR, 2.48). In addition, we found that an
elevated fibrinogen level was inversely associated with DVT risk in patients with early stroke.35 This
observation was opposite to the finding that elevated CRP, another acute-phase prognostic factor, showed
an association with DVT risk. The authors speculated that this finding may be a result of fibrinogen
depletion due to active clot formation.35 We believe that such reverse causation, given the study design,
may be plausible. However, given the small sample size, the finding warrants further investigations in
primary studies. In terms of bleeding, the candidate prognostic factor antithrombotic use showed mixed
results in the different studies and was included only in 1 final model.32 However, we identified a probable
association with the outcome when the individual results were subjected to meta-analysis,8,25,33 perhaps
because of the limitation of the databases used that may not include all potential prognostic factors.
Another reason that their findings may have been limited is the methods used in the development of RAMs
for the multivariate analysis, such as automated procedures (eg, backward or forward) used for prognostic
factor selection or selection of factors based on statistical significance at the univariate analysis stage.
Therefore, the findings in our study ensure the consideration of all identified potential prognostic factors in
the literature during the development of a RAM, a better assessment of the databases being used, and the
comprehensiveness of the factors included in the databases. Studies in this systematic review included
patients who received thromboprophylaxis, which may have altered the risk estimates. However, we
controlled for the use of thromboprophylaxis in several ways. We selected studies only if they included a
small fraction of patients receiving thromboprophylaxis (less than 10%) or if it was controlled for in the
statistical analysis. Beyond that, given the general assumption that the relative risk related to a prognostic
factor remains largely unaffected by administration of thromboprophylaxis (although the baseline risk of
course might change), we used relative estimates of the risk. This assumption is supported by the
observation that, in several studies, the relative estimates of risk were not influenced by adjustment for
prophylaxis use in the statistical analyses. We believe that these measures should address the influence of
thromboprophylaxis on the prognostic factor we addressed herein.
Implications for future research
Research may be needed to reevaluate existing RAMs, as the developers of the models may not have been
able to use the variables we identified, given the limitations in the existing databases. However, a full
development or improvement of a RAM that supports clinical practice requires further investigation of all
the prognostic factors we identified in our study.

Conclusion
In this systematic review, we identified all reported relevant prognostic factors for VTE and bleeding in
hospitalized medical patients. Some of these factors are not part of current risk prediction for VTE and
bleeding in hospitalized medical patients. Our findings will help inform experts in developing populationbased guidelines and accurate, user-friendly RAMs to better guide individual patient prophylactic
management.
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Figure 1.
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Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart.
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Table 1.
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Open in a separate window
BI, Barthel Index; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CTA, computed
tomographic angiography; GI, gastrointestinal; ICD-9-CM, International Classification of Diseases, Ninth Revision,
Clinical Modification; IVC, inferior vena cava; LWMH, low-molecular-weight heparin; mRS, modified Rankin
Score; NYHA, New York Heart Association; RBC, red blood cell.

*
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*

Caprini factors: stroke; acute spinal cord injury or paralysis (<1 mo); hip, pelvis, or leg fracture (<1 mo); multiple
trauma (<1 mo); age ≥75); history of VTE; family history of VTE; history of thrombophilia; heparin-induced
thrombocytopenia; age (41-60); age (61-74); positive history of cancer; immobilizing plaster cast; congestive heart
failure; COPD or pulmonary function; inflammatory bowel disease; severe long disease (including pneumonia); acute
myocardial infarction; sepsis (<1 mo); surgery (<1 mo); postpartum (<1 mo); history of unexpected stillborn infant,
recurrent spontaneous abortion (≥ 3) or premature birth; varicose veins; BMI >25 kg/m2; swollen legs (current); CVC
present on admission; immobile or not ambulating; and hormone replacement therapy or oral contraceptives.
†
Padua factors: active cancer; previous VTE; reduced mobility; known thrombophilia; recent trauma and /or surgery;
elderly age; heart and/or respiratory failure; acute myocardial infarction or ischemic stroke; acute infection and/or
rheumatologic disorder; obesity; ongoing hormone treatment, and VTE prophylaxis.
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Table 2.
Evidence profile for VTE-related prognostic factors
No. of

Certainty assessment domains

studies
Study design

Risk of
bias

Overall

Relative

certainty in

effect

Indirect Inconsistent Imprecise Publication the evidence
about this
bias

(95% CI

prognostic
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7,25-27,29,31,34,37,39
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*
†
9
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Not serious
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OR, 1.34
(95% CI
1.17-1.55

27,34-37
Sex (male vs female)
5

Observational

Serious

Not

Not serious

serious

Not
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MODERATE

OR, 1.03
(95% CI,
0.80-1.33)

35
CRP (>10 mg/L vs <10 mg/L)
1

Observational

Serious

Not

Not serious

serious

Not

⊕⊕⊕○

Undetected

serious

MODERATE

36,39
D-dimer (>500 ng/mL vs <500 ng/mL at baseline; and increase vs no increase)
†
2
Observational Serious
Not
Not serious
Not
Undetected
serious

⊕⊕⊕○

serious

OR, 10.1
(95% CI
1.93-52.8

Categoric
OR, 2.46
(95% CI
1.19-5.10

MODERATE Continuou
OR, 3.45
(95% CI
2.01-5.92
27
Heart rate (elevated >100 beats per minute vs nonelevated <100 beats per minute)
1

Observational

Serious

Not

Not serious

serious

Not

Undetected

serious

⊕⊕⊕○
MODERATE

OR, 2.48
(95% CI
1.66-3.71

9
9 27,28
Thrombocytosis (platelet count >350 × 10 /L vs <350 × 10 /L)
2

Observational

Serious

Not

Not serious

Not

Undetected

⊕⊕⊕○

OR 2 16

Open in a separate window
Question: prognostic factors for medical patients; outcome: VTE; setting: inpatient.
BI, Barthel Index; WBC, white blood cell count.
*

Certainty in evidence was downgraded for risk of bias, given a follow-up time of more than 3 months in the included
studies that may cause an overestimation of the magnitude of the association (Zhou et al29: 6 mo after discharge and
Yi 2012: 12 mo after discharge).
†
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable

20/24

9/23/2020

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis
†

Certainty in evidence was downgraded for imprecision, given that the confidence interval suggests that there may be
no association.
‡
Certainty in evidence was downgraded for risk of bias, given that the results of each prognostic factor in the
multivariate analysis were not reported and we therefore had to rely on the unadjusted measures of association. Also,
the multivariate analysis included only factors statistically significant in the univariate analysis.
§
Certainty in evidence was downgraded for inconsistency but not imprecision, given that the inconsistency is the
likely cause for the imprecision.
||
Certainty in evidence was downgraded for imprecision, given the small number of events (n = 32).
¶
Bembenek et al35 assessed the severity of a stroke experienced by an individual by using the NIHSS, a diagnostic
tool; results were consistent with the meta-analysis that severe stroke may result in an increase in risk of any DVT
(OR, 2.11; 95% CI,: 0.50-8.90) for NIHSS >7 compared with a NIHSS score <7. Also, severe stroke may result in an
increase in risk of any DVT (OR, 1.34; 95% CI,: 0.25-7.18) for NIHSS >14 compared with a NIHSS <14. When
NIHSS was assessed continuously, results showed that severe stroke may result in an increase in risk of any DVT
(OR, 1.21; 95% CI,: 0.86-1.70) for each additional 4 points on the NIHSS.
#
Fan et al,36 with 458 patients older than 60 y of which 45 patients had any VTE, presented age as a continuous
variable and showed no association between age and any VTE (OR, 1.03; 95% CI, 0.98-1.08). Bembenek et al,35 with
299 patients of which 9 had any DVT, 7 of which were distal, presented age per 10-y increase and showed a decrease
in risk per 10-y increase in age with any DVT (OR, 0.64; 95% CI, 0.33-1.24).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable

21/24

9/23/2020

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable

22/24

9/23/2020

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Table 3.
Evidence profile for bleeding-related prognostic factors
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Question: prognostic factors for medical patients; outcome: bleeding; setting: inpatient.
*

Certainty in evidence was downgraded for risk of bias, given that patients were enrolled both prospectively and
retrospectively in Decousus et al.8 The retrospective enrollment of patients may have introduced classification bias.

†
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242782/?report=printable
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Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis
†

Certainty in evidence was downgraded for risk of bias, given that the authors evaluated bleeding risk in medical
patients after hospitalization, that may overestimate the magnitude of the association. This is possibly due to patients
being discharged on thromboprophylaxis without proper risk stratification for bleeding placing unmonitored patients
at a higher risk of having a bleeding event.
‡
Certainty in evidence was downgraded for risk of bias, given that the population is specific to hospitalized cancer
patients who are at a higher risk of VTE and may be given thromboprophylaxis, placing them at a higher risk of
having a bleeding event. This in turn may overestimate the magnitude of the association.
§
Certainty in evidence was downgraded for imprecision, given that the CI suggests that there may be no association.
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